The American Society of Anesthesiologists held its Annual Meeting in Orlando, Florida on October 17-21, 1998. BioTime, Inc. (OTC: BTIM) (Price: $10.625) presented two posters at this conference. A poster session titled “Comparison of Intraoperative Administration of Hextend® Versus Hespan® for the Treatment of Hypovolemia During Major Surgery” was presented in the morning on October 20th. A Poster-Discussion session was held in the afternoon on October 20th titled “The Effects of Hextend® and Hespan® on Thromboelastography.”
Neither of these posters nor their abstracts contained any new data concerning the results of Hextend’s clinical trial. Claims that posters contained new data that support the belief that Hextend has any safety, including reduced bleeding, or any other advantage over Hespan products are entirely false. In addition, there was no mention of BioTime or Hextend in any literature or sign posted in the Abbot conference booth. There was no claim that Hextend was coming soon or that FDA approval is imminent.
Short selling involves a risk not associated with the purchase of stock including, but not only limited to, unlimited loss and stock borrowing risks. Additional information is available upon request.